Figure 5.
Figure 5. Peripheral blood platelet counts. C3H/HeN LPS–sensitive (A) and C3H/HeJ LPS–resistant (B) mice. LPS and anti-CD61 nontreated control group (•), LPS-treatment alone group (○), anti-CD61–treated, LPS-treated group (□), anti-CD61–treated group with a transfusion of 108 platelets from CD61-KO mice (⋄), and anti-CD61–treated, LPS-treated group with a transfusion of 108 platelets from CD61-KO mice group (▿) are shown. Platelet counts were measured by flow cytometry at the indicated times on the x-axis. Arrows indicate treatment schedule times. Data are expressed as the mean ± SD platelet count in 5 mice per group.

Peripheral blood platelet counts. C3H/HeN LPS–sensitive (A) and C3H/HeJ LPS–resistant (B) mice. LPS and anti-CD61 nontreated control group (•), LPS-treatment alone group (○), anti-CD61–treated, LPS-treated group (□), anti-CD61–treated group with a transfusion of 108 platelets from CD61-KO mice (⋄), and anti-CD61–treated, LPS-treated group with a transfusion of 108 platelets from CD61-KO mice group (▿) are shown. Platelet counts were measured by flow cytometry at the indicated times on the x-axis. Arrows indicate treatment schedule times. Data are expressed as the mean ± SD platelet count in 5 mice per group.

Close Modal

or Create an Account

Close Modal
Close Modal